Ed Arce
Stock Analyst at HC Wainwright & Co.
(3.43)
# 973
Out of 4,732 analysts
444
Total ratings
41.52%
Success rate
6.07%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ed Arce
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Reiterates: Neutral | $5.5 | $5.01 | +9.78% | 8 | Jan 16, 2025 | |
| AKRO Akero Therapeutics | Reiterates: Buy | $50 | $25.14 | +98.89% | 23 | Jan 16, 2025 | |
| AKBA Akebia Therapeutics | Reiterates: Buy | $7.5 | $2.07 | +262.32% | 33 | Jan 14, 2025 | |
| NAMS NewAmsterdam Pharma Company | Reiterates: Buy | $48 | $23.55 | +103.82% | 2 | Jan 14, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $390 → $400 | $293.64 | +36.22% | 16 | Jan 14, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Buy | $63 | $16.79 | +275.22% | 27 | Jan 13, 2025 | |
| ACXP Acurx Pharmaceuticals | Reiterates: Buy | $12 | $0.88 | +1,259.00% | 16 | Jan 13, 2025 | |
| UNCY Unicycive Therapeutics | Maintains: Buy | $4 | $0.62 | +545.16% | 24 | Jan 8, 2025 | |
| MTVA MetaVia | Initiates: Buy | $12 | $1.95 | +516.97% | 1 | Dec 30, 2024 | |
| GALT Galectin Therapeutics | Downgrades: Neutral | n/a | $1.24 | - | 16 | Dec 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $14.49 | - | 7 | Dec 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $95 | $40.00 | +137.50% | 4 | Dec 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $18 | $5.25 | +242.86% | 10 | Dec 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $7.5 | $4.43 | +69.30% | 11 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $3.20 | +56.25% | 17 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $4.39 | +628.93% | 9 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $0.85 | - | 12 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $66 | $46.95 | +40.58% | 29 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $24 | $21.70 | +10.60% | 21 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $29 | $6.31 | +359.59% | 20 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $11.21 | +238.98% | 20 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $75 | $34.24 | +119.04% | 4 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $13 | $2.16 | +501.85% | 13 | Oct 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $3.47 | +274.64% | 17 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $18 | $18.37 | -2.01% | 19 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $1.54 | +224.68% | 13 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $8.01 | +62.30% | 16 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $6 | $0.67 | +795.52% | 4 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 → $240 | $1.42 | +16,801.41% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $1.46 | - | 8 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $33.37 | -25.08% | 8 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.90 | - | 4 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $19.03 | - | 2 | Nov 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13,500 → $14,625 | $1.85 | +790,440.54% | 2 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $7 | $32.65 | -78.56% | 1 | Nov 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $33.35 | -37.03% | 1 | Sep 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.37 | - | 2 | Feb 15, 2017 |
Ardelyx
Jan 16, 2025
Reiterates: Neutral
Price Target: $5.5
Current: $5.01
Upside: +9.78%
Akero Therapeutics
Jan 16, 2025
Reiterates: Buy
Price Target: $50
Current: $25.14
Upside: +98.89%
Akebia Therapeutics
Jan 14, 2025
Reiterates: Buy
Price Target: $7.5
Current: $2.07
Upside: +262.32%
NewAmsterdam Pharma Company
Jan 14, 2025
Reiterates: Buy
Price Target: $48
Current: $23.55
Upside: +103.82%
Madrigal Pharmaceuticals
Jan 14, 2025
Maintains: Buy
Price Target: $390 → $400
Current: $293.64
Upside: +36.22%
Arcturus Therapeutics Holdings
Jan 13, 2025
Reiterates: Buy
Price Target: $63
Current: $16.79
Upside: +275.22%
Acurx Pharmaceuticals
Jan 13, 2025
Reiterates: Buy
Price Target: $12
Current: $0.88
Upside: +1,259.00%
Unicycive Therapeutics
Jan 8, 2025
Maintains: Buy
Price Target: $4
Current: $0.62
Upside: +545.16%
MetaVia
Dec 30, 2024
Initiates: Buy
Price Target: $12
Current: $1.95
Upside: +516.97%
Galectin Therapeutics
Dec 27, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.24
Upside: -
Dec 27, 2024
Reiterates: Neutral
Price Target: n/a
Current: $14.49
Upside: -
Dec 24, 2024
Reiterates: Buy
Price Target: $95
Current: $40.00
Upside: +137.50%
Dec 24, 2024
Maintains: Buy
Price Target: $27 → $18
Current: $5.25
Upside: +242.86%
Dec 4, 2024
Reiterates: Neutral
Price Target: $7.5
Current: $4.43
Upside: +69.30%
Nov 18, 2024
Reiterates: Buy
Price Target: $5
Current: $3.20
Upside: +56.25%
Nov 15, 2024
Reiterates: Buy
Price Target: $32
Current: $4.39
Upside: +628.93%
Nov 14, 2024
Reiterates: Neutral
Price Target: n/a
Current: $0.85
Upside: -
Nov 13, 2024
Reiterates: Buy
Price Target: $66
Current: $46.95
Upside: +40.58%
Nov 11, 2024
Reiterates: Buy
Price Target: $24
Current: $21.70
Upside: +10.60%
Nov 11, 2024
Reiterates: Buy
Price Target: $29
Current: $6.31
Upside: +359.59%
Nov 8, 2024
Reiterates: Buy
Price Target: $38
Current: $11.21
Upside: +238.98%
Nov 7, 2024
Reiterates: Buy
Price Target: $75
Current: $34.24
Upside: +119.04%
Oct 15, 2024
Maintains: Buy
Price Target: $14 → $13
Current: $2.16
Upside: +501.85%
Oct 11, 2024
Reiterates: Buy
Price Target: $13
Current: $3.47
Upside: +274.64%
Sep 27, 2024
Maintains: Buy
Price Target: $23 → $18
Current: $18.37
Upside: -2.01%
Sep 10, 2024
Reiterates: Buy
Price Target: $5
Current: $1.54
Upside: +224.68%
Sep 6, 2024
Reiterates: Buy
Price Target: $13
Current: $8.01
Upside: +62.30%
Aug 16, 2024
Reiterates: Buy
Price Target: $6
Current: $0.67
Upside: +795.52%
Mar 26, 2024
Reiterates: Buy
Price Target: $12 → $240
Current: $1.42
Upside: +16,801.41%
Mar 20, 2024
Upgrades: Neutral
Price Target: n/a
Current: $1.46
Upside: -
Dec 27, 2023
Reiterates: Buy
Price Target: $25
Current: $33.37
Upside: -25.08%
May 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $2.90
Upside: -
Nov 18, 2020
Downgrades: Neutral
Price Target: n/a
Current: $19.03
Upside: -
May 12, 2020
Maintains: Buy
Price Target: $13,500 → $14,625
Current: $1.85
Upside: +790,440.54%
Nov 10, 2017
Assumes: Buy
Price Target: $7
Current: $32.65
Upside: -78.56%
Sep 11, 2017
Initiates: Buy
Price Target: $21
Current: $33.35
Upside: -37.03%
Feb 15, 2017
Downgrades: Neutral
Price Target: n/a
Current: $3.37
Upside: -